Skip to Content
Top

BY Scott Merville

Approaches to cancer treatment developed by MD Anderson researchers as part of the institution’s Moon Shots Program will be, in part, the focus of two new Dream Teams announced by Stand Up to Cancer (SU2C), a national organization launched by film and media leaders to speed development of cancer treatments.

The researchers will test combinations of targeted therapy and immunotherapy against lung cancer driven by intractable KRAS...

John Heymach, M.D., Ph.D., lung cancer and Karen Lu, M.D. breast and ovarian cancer

BY Scott Merville

Immunotherapy is complex, has curative potential for some patients when given alone or combined with other drugs, and needs further support...

BY Ron Gilmore

Think of a waterfall, and you might see why cell-signaling pathways are important to cancer research. As water cascades, it impacts everything...

BY Katrina Burton

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country’s health care system.

The prediction comes from a cost-effectiveness analysis led by researchers at MD Anderson. The findings, reported in the Annals of Internal Medicine, predict that the cost of providing patients their daily regimens could total $90 billion over five...

hepatitis C liver cancer

BY Laura Sussman

The good news is death rates continue to decline for the most common types of cancer, including lung, colon, breast and prostate.

The...

BY Laura Sussman

In a study of women with high-grade uterine cancer, researchers at MD Anderson Cancer Center found sentinel lymph node (SLN) mapping accurately...

BY MD Anderson staff

A new research platform of MD Anderson’s Moon Shots Program will lead a collaboration with an international pharmaceutical company to develop...

BY Scott Merville

James Allison, Ph.D., chair of Immunology at MD Anderson Cancer Center, was awarded the 2015 Paul Ehrlich and Ludwig Darmstaedter Prize Saturday...

BY Allison Ignacio

Christopher Logothetis, M.D., chair and professor of Genitourinary Medical Oncology, is the recipient of the inaugural Finneran Family Prize...